Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30198151 | 1.00 | GPR119 (0.60) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL15584576 | 0.95 | GPR119 (0.56) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL29660540 | 0.95 | GPR119 (0.56) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL29475574 | 0.87 | GPR119 (0.62) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL25317395 | 0.87 | GPR119 (0.62) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL6495092 | 0.86 | PARP14 (0.59) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL12082170 | 0.86 | GPR119 (0.79) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL30208161 | 0.86 | GPR119 (0.79) | GPR119MAPTALDH1A1LMNAPDK2 | |
| SCHEMBL30208156 | 0.86 | MAPT (0.63) | GPR119MAPTALDH1A1LMNA | |
| SCHEMBL1958401 | 0.86 | GPR119 (0.60) | GPR119MAPTALDH1A1LMNAPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2026-05-07 | — | — | US | disclosed |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | CELGENE CORPORATION (US) | 2026-01-29 | — | — | US | disclosed |
| US-12521440-B2 | Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BEONE MEDICINES I GMBH (CH) | 2026-01-13 | — | — | US | disclosed |
| US-12516055-B2 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | TRUSTEES OF TUFTS COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE SWITZERLAND GMBH (CH) | 2025-06-26 | — | — | US | disclosed |
| EP-4574823-A1 | COMPOUNDS FOR INHIBITING OR DECOMPOSING CDK2 AND/OR CDK9, AND MEDICINAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2025-06-25 | — | — | EP | disclosed |
| EP-4562012-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| US-6503925-B1 | Treating anxiety, anesthesia, and epilepsy | NEUROSEARCH A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| CN-1356987-A | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | NEUROSEARCH AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| CN-1334808-A | Benzamide derivatives and their use as inhibitors of APOB-100 secretion | GLAXO GROUP LTD (GB) | 2002-02-06 | — | — | CN | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| US-6218547-B1 | 1-phenyl-benzimidazole compounds and their use as GABA-a receptor modulators | NEUROSEARCH A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AR, NR5A1, CYP17A1 | GPR119 149/4885MAPT 3565/4885ALDH1A1 756/4885 |
| US-20260028343-A1 | Substituted Imidazopyrazine Compounds as Ligand Directed Degraders of IRAK3 | IRAK3, IRAK2, IRAK1 | GPR119 1849/4885MAPT 4371/4885ALDH1A1 1519/4885 |
| US-20260125382-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING CDK2 AND/OR CDK9 AND MEDICINAL USE THEREOF | CDK9, CDK20, CDK19 | GPR119 1956/4885MAPT 4335/4885ALDH1A1 3278/4885 |
| US-20250205345-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | GPR119 4296/4885MAPT 3793/4885ALDH1A1 4351/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | GPR119 385/4885MAPT 981/4885ALDH1A1 1345/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | GPR119 1512/4885MAPT 1893/4885ALDH1A1 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.